These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24636845)

  • 1. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?
    Godeau B; Stasi R
    Presse Med; 2014 Apr; 43(4 Pt 2):e79-85. PubMed ID: 24636845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depletion in immune thrombocytopenia.
    Godeau B
    Semin Hematol; 2013 Jan; 50 Suppl 1():S75-82. PubMed ID: 23664523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recurrent infections in an ITP patient treated with rituximab].
    Rosenberg-Bezalel S; Asher I; Sthoeger Z
    Harefuah; 2012 Nov; 151(11):617-9, 655. PubMed ID: 23367730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
    Gómez-Almaguer D
    Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F; Ruggeri M
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia.
    Audia S; Rossato M; Trad M; Samson M; Santegoets K; Gautheron A; Bekker C; Facy O; Cheynel N; Ortega-Deballon P; Boulin M; Berthier S; Leguy-Seguin V; Martin L; Ciudad M; Janikashvili N; Saas P; Radstake T; Bonnotte B
    J Autoimmun; 2017 Feb; 77():89-95. PubMed ID: 27863820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia.
    Guo L; Kapur R; Aslam R; Speck ER; Zufferey A; Zhao Y; Kim M; Lazarus AH; Ni H; Semple JW
    Blood; 2016 Feb; 127(6):735-8. PubMed ID: 26556550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
    Pescovitz MD
    Am J Transplant; 2006 May; 6(5 Pt 1):859-66. PubMed ID: 16611321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
    Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
    Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
    Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.
    von Laer Tschudin L; Schwitzgebel VM; von Scheven-Gête A; Blouin JL; Hofer M; Hauschild M; Ansari M; Stoppa-Vaucher S; Phan-Hug F
    Pediatr Diabetes; 2015 Mar; 16(2):138-45. PubMed ID: 24552605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
    Aggarwal A; Catlett JP
    South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura.
    Koene HR
    Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):703-5. PubMed ID: 16933273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.
    Stasi R; Del Poeta G; Stipa E; Evangelista ML; Trawinska MM; Cooper N; Amadori S
    Blood; 2007 Oct; 110(8):2924-30. PubMed ID: 17548576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term impact of rituximab for childhood immune thrombocytopenia.
    Cooper N; Bussel JB
    Curr Rheumatol Rep; 2010 Apr; 12(2):94-100. PubMed ID: 20425017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective B cell depletion with rituximab in the treatment of autoimmune diseases.
    Kneitz C; Wilhelm M; Tony HP
    Immunobiology; 2002 Dec; 206(5):519-27. PubMed ID: 12607727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advances in pathophysiology and treatment of immune thrombocytopenia].
    Kashiwagi H; Tomiyama Y
    Rinsho Ketsueki; 2015 Feb; 56(2):177-84. PubMed ID: 25765798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.